

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AstraZeneca AB	02/08/2011
RECEIVING PARTY DATA	
Name:	MedImmune Limited
Street Address:	Milstein Building
Internal Address:	Granta Park
City:	Cambridge
State/Country:	UNITED KINGDOM
Postal Code:	CB21 6H
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	12376052
Application Number:	12708022
Application Number:	60835647
Patent Number:	7754859
CORRESPONDENCE DATA	
Fax Number:	(301)398-9306
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	301-398-0000
Email:	ipdocketing@medimmune.com
Correspondent Name:	MedImmune
Address Line 1:	One MedImmune Way
Address Line 4:	Gaithersburg, MARYLAND 20878
ATTORNEY DOCKET NUMBER:	MED0281
NAME OF SUBMITTER:	Rachel Caputo

CH \$160.00 12376052

501434806

PATENT
REEL: 025790 FRAME: 0916

Total Attachments: 7

source=MED0281#page1.tif

source=MED0281#page2.tif

source=MED0281#page3.tif

source=MED0281#page4.tif

source=MED0281#page5.tif

source=MED0281#page6.tif

source=MED0281#page7.tif

PATENT

REEL: 025790 FRAME: 0917

DEED OF ASSIGNMENT

This Deed of Assignment is made effective as of the 1st day of April 2008 (the "Effective Date") by and between:

(1) ASTRAZENECA AB, a company incorporated in Sweden under No. 556011-7482 with offices at S-151 85 Södertälje, Sweden ("AZAB"); and

(2) MEDIMMUNE LIMITED, a company incorporated in England under No. 2451177 whose registered office is at Milstein Building, Granta Park, Cambridge, CB1 6GH, England ("MedI Ltd").

Recitals

WHEREAS, AZAB, is the owner of and desires to assign and transfer to MedI Ltd the entire right, title and interest in and to the patents and patent applications identified in Schedule A attached hereto, the inventions covered thereby, and priority rights claimed therein or corresponding thereto, including any and all extensions, supplementary protection certificates, renewals, reissues, continuations, continuations-in-part, conversions, divisions, inventor's certificates and prolongations thereof, and including the right to sue under said patents, and patents that may be granted on said applications, for infringement occurring before the date of this assignment and to recover and retain any damages or profits as a result therewith (individually and collectively "Patents"); and

WHEREAS, MedI Ltd is desirous of acquiring the entire right, title and interest in and to said Patents;

NOW, WITNESSETH, that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged:

As of the Effective Date, AZAB hereby assigns, transfers and sets over unto MedI Ltd, its successors, legal representatives and assigns, the entire right, title and interest, in and to said Patents, for all countries of the world, the same to be held and enjoyed by MedI Ltd, its successors, assigns, and legal representatives.

AZAB hereby authorizes and requests any official of any country, whose duty it is to issue patents on applications, to issue each and every letters patent to be granted that is a Patent, and each and every reissue, conversion, or prolongation of said letters patent, to MedI Ltd, its successors, legal representatives and assigns, as the assignee of the AZ AB's entire right, title and interest therein.

AZAB hereby agrees to execute, and direct its representatives, successors and assigns to execute, any and all further papers which MedI Ltd may consider necessary or desirable to vest or perfect the title of MedI Ltd and its successors, assigns or legal representatives in and to said Patents, or for maintaining, enforcing or defending same.

PATENT


REEL: 025790 FRAME: 0918

THIS DEED OF ASSIGNMENT shall be governed by and construed in accordance with the laws of England.

THIS DEED OF ASSIGNMENT IS EXECUTED as a Deed by the authorized representatives of the parties effective as of the date first written above.

SIGNED for and on behalf of

AstraZeneca AB


Authorized signature

Name: Patrick Scott Alban

Title: Power of Attorney

Date: February 8, 2011

SIGNED for and on behalf of

MedImmune Limited


Authorized signature

Name: Patrick Scott Alban

Title: Power of Attorney

Date: February 8, 2011

In the Presence of:



Signature

Name: Rachel Caputo

Address: One MedImmune Way
Gaithersburg, MD 20878

Date: 2/8/11

In the Presence of:


Signature

Name: Rachel Caputo

Address: One MedImmune Way
Gaithersburg, MD 20878

Date: 2/8/11

SCHEDULE A

Specific Patents and Patent Applications

DOCKET NO.	COUNTRY	APPLICATION NO.	FILING DATE	PATENT NUMBER	TITLE
MED0281.2US	US	12/376,052	2-Feb-09		TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.3DIV	US	12/708,022	18-Feb-10		TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.AR	AR	70103450	3-Aug-07		TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.AU	AU	2007348940	2-Aug-07		TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.BR	BR	PI0715223-0	2-Aug-07		TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF

MED0281.CA	CA	2,657,898	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.CL	CL	2225/2007	31-Jul-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.CN	CN	200780028101.8	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.EP	EP	7873957	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.HK	HK	9106174.6	9-Jul-09	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.IL	IL	196209	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF

MED0281.IN	IN	43/MUMNP/2009	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.JP	JP	2009-523063	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.KR	KR	2009/7002482	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.MX	MX	2009/001021	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.NO	NO	20090069	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.NZ	NZ	575245	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF

MED0281.PCT	WO	PCT/US2007/075117	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.PK	PK	929/2007	3-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.PRO	US	60/835,647	3-Aug-06	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.SA	SA	7280426	4-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.SG	SG	200900762-6	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.TH	TH	701003854	2-Aug-07	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF

MED0281.TW	TW	96128380	2-Aug-07		TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.US	US	11/833,473	3-Aug-07	7754859	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.UY	UY	30525	3-Aug-07		TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.VE	VE	1689/2007	3-Aug-07		TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
MED0281.ZA	ZA	2009/00461	2-Aug-07	2009/00461	TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF